1. Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care? 
Arjan C. Lankester, Franco Locatelli, Peter Bader, Eva Rettinger, Maarten Egeler, Satyendra Katewa, Michael A. Pulsipher, Stefan Nierkens, Kirk Schultz, Rupert Handgretinger, Stephan A. Grupp, Jaap Jan Boelens, Catherine M. Bollard 
Biology of Blood and Marrow Transplantation 
Volume 21, Issue 3, Pages (March 2015)
DOI: /j.bbmt
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
A CAR consists of a single chain variable fragment of an antibody (scFv) that recognizes a protein (such as CD19 on B cells and ALL cells) coupled to the CD3 ζ activation domain and costimulatory domains from CD28 and/or 4-1BB. This combines the MHC-independent recognition of a tumor antigen with the activating potential of T cell receptor signaling, allowing for redirection of T cells to cancer cells and extensive in vivo proliferation.
© Sue Seif. Reproduced with permission.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions